Ruxolitinib cream was approved for moderate atopic dermatitis in non-immunocompromised patients aged 2 years and older. The phase 3 TRuE-AD3 study showed significant efficacy and safety in children ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback